Eureka Project Is Now Wooing Venture Capital

Paris—The French-inspired Eureka program is hoping to forge links with the world of venture capital to finance a series of cooperative industrial research and development projects throughout Europe. The 2-year-old program features 108 projects involving industrial firms from at least two European countries. Member governments agree to help their own national companies, typically through subsidies, but do not provide direct financial aid. As a consequence, several small and medium-sized com

Written byJacques Richardson
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The 2-year-old program features 108 projects involving industrial firms from at least two European countries. Member governments agree to help their own national companies, typically through subsidies, but do not provide direct financial aid. As a consequence, several small and medium-sized companies are finding their finances strained by their involvement in such high-risk fields as biotechnology and robotics. "Eureka is now reaching the stage where outside funding can be involved," Eduardo Months of the Spanish Center for Technological and Industrial Development told a recent meeting in Madrid of the European Venture Capital Association. For some projects, Months said, such outside support is crucial. His comments came on the heels of a study by Britains Cranfield Institute of Technology that criticized Sweden, Denmark and the United Kingdom as being stingy in providing credits to companies involved in Eureka projects.

The idea behind Eureka is to keep science-based industry in the Old ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies